January 12, 2024 Release Highlights Copied

Practice Insights is pleased to announce updates in the application to support the Merit-Based Incentive Payment System (MIPS).

MIPS Quality Measures Dashboard

The dashboard has been updated to reflect the below refinement(s) for:

Measure	Description
PIMSH #15: Antiemetic Therapy for Low-and-Minimal-Emetic Risk Antineoplastic Agents in the Infusion Center-Avoidance of Overuse (Inverse Measure)	A technical refinement was made to remove retired providers/clinicians from displaying in the dashboard. It will now only show the actual clinician providing services to the patient.	Practices will notice a slight shift in numerator or denominator.
PIMSH #16: Appropriate Antiemetic Therapy for High-and Moderate-Emetic-Risk Antineoplastic Agents in the Infusion Center	A technical refinement was made to remove retired providers/clinicians from displaying in the dashboard. It will now only show the actual clinician providing services to the patient.	Practices will notice a slight shift in numerator or denominator.
MIPS #450: Trastuzumab Received by Patients with AJCC Stage I (T1c), II and III and HER2+ Breast Cancer Receiving Adj Chemo	Code refinement to look for targeted therapy within 6 months of a cancer diagnosis.	Practices will notice a shift in the numerator.
MIPS Benchmark File	The Benchmarks within Practice Insights MIPS Quality Measure Dashboard will now display 7 points for the following measures: MIPS#462 PIMSH#8 PIMSH#15 PIMSH#16 The following measures will receive 0 points within the dashboard: MIPS#104 MIPS#128 MIPS#451 MIPS#452	Practices will not see numerator or denominator changes.

Status of Dashboard Updates for 2023

CMS releases updates to the quality measure specifications annually for the MIPS program. These measure specifications have been reviewed, and Practice Insights is working on the required technical updates to align with the revised requirements. McKesson will continue to notify practices once measures have been updated based on the current 2023 requirements. The measures listed below either have no 2023 update required or have been updated.

Measure	Description
MIPS Quality Measures Dashboard
#047	Advance Care Plan
#104	Adjuvant Hormonal Therapy for High-Risk or Very High-Risk Prostate Cancer
#130	Current Medications Documentation
#134	Preventive Care Screening: Screening for Depression and Follow-Up Plan
#143	Pain Intensity Quantified
#144	Pain Care Plan
#226	Tobacco Screening and Cessation
#236	Controlling High Blood Pressure
#238	Use of High-Risk Meidcations in Older Adults
#374	Closing the Referral Loop
#450	Trastuzumab Received by Patients with AJCC Stage I (T1c), II and III and HER2+ Breast Cancer Receiving Adj Chemo
#451	RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who Receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy
#452	Percentage of Adult Patients (aged 18 or older) with Metastatic Colorectal Cancer and RAS (KRAS & NRAS) Gene Mutation Spared Treatment with Anti-EGFR Monoclonal Antibodies
#453	Percentage of Patients who Died from Cancer Receiving Systemic Cancer-Directed Therapy in the Last 147 Days of Life (Inverse Measure)
#457	Patients Admitted to Hospice for < 3 Days
#462	Bone Density Evaluation of Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy
PIMSH#1	Advance Care Planning in Stage 4 Disease
PIMSH#2	Utilization of GCSF in Metastatic Colon/Rectal Cancer (Inverse Measure)
PIMSH#4	Patient-Reported Pain Improvement
PIMSH#8	Mutation Testing for Lung Cancer
PIMSH#9	Supportive Care Drug Utilization in the Last 14 Days of Life (Inverse Measure)
PIMSH#10	Hepatitis B Serology Testing for Prophylactic Treatment Prior to Receiving Anti CD20 Targeting Drugs
PIMSH#15	Antiemetic Therapy for Low-and-Minimal-Emetic Risk Antineoplastic Agents in the Infusion Center-Avoidance of Overuse (Inverse Measure)
PIMSH#16	Appropriate Antiemetic Therapy for High-and Moderate-Emetic-Risk Antineoplastic Agents in the Infusion Center